16 results about "Prothrombinase" patented technology

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.

We provide new monoclonal antibody inhibitors of coagulases, staphylocoagulase (“SC”) and von Willebrand factor-binding protein (“vWbp”) for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and / or inhibit the binding interactions between the coagulase protein and its ligan protein prothrombin the activation of prothrombin.

The present invention relates to a method for producing thrombin from a thromboplastin source using a given BaSO4 reagent as an adsorbent for prothrombin, and a method for assessing the suitability of a given BaSO4 reagent for the preparation of thrombin. In at least one embodiment, the method comprises contacting a sample of the given BaSO4 reagent with a thromboplastin source to obtain BaSO4-adsorbed thromboplastin, and subsequently assessing the procoagulant activity of the BaSO4-adsorbed thromboplastin. In another embodiment, the method comprises the step of assessing the procoagulant activity relative to normal mammalian plasma.

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.

The invention discloses a method for establishing a rat bionic model for sudden deafness caused by inner ear microcirculation disturbance, and relates to the technical field of animal model construction.The method comprises the steps that exosome extraction and purification are conducted, specifically, healthy rat bone marrow is obtained, mesenchymal stem cells are extracted and placed in a culture bottle to be cultured, cell culture supernate is collected, and the exosome is obtained; extracting exosomes by adopting an ultracentrifugation method; loading of the procoagulant factor and the exosome: selecting a prothrombin fragment as the procoagulant factor, treating the prothrombin fragment, and mixing the obtained exosome resuspension and the prothrombin fragment solution according to the volume ratio of 1: 1. The exosome derived from the mesenchymal stem cells is adopted as a procoagulant factor carrier, the source is wide, and the exosome is easy to obtain; the exosome is stable in yield and good in biocompatibility, damage to inner ear tissues of rats can be reduced, and the exosome has natural targeting transportation capacity and can be specifically combined with inner ear vascular endothelial cells, so that the concentration of a procoagulant factor at a target site is increased, and the accuracy of model establishment is enhanced.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

The invention relates to a composition for stabilizing a human prothrombin complex and application of the composition. The composition comprises an anticoagulant and a protective agent, the anticoagulant is heparin and / or a pharmaceutically acceptable salt thereof; the protective agent is selected from arginine and / or histidine and one or more of their respective pharmaceutically acceptable salts, and the ratio of the anticoagulant to the protective agent is (4.5-9.5) IU: (0.02-0.04) g. The activity of FII, FVII, FIX and FX of the prothrombin complex preparation prepared by adopting the composition for stabilizing the human prothrombin complex provided by the invention is not obviously reduced even under the condition of high temperature (40 + / -2 DEG C), and the activity of the FII, the FVII, the FIX and the FX is not obviously reduced after the prothrombin complex preparation is stored at the high temperature for at least 24 months. The biological activity index of the prothrombin complex preparation still meets the clinical use standard.

The invention relates to the technical field of biological medicine, and provides a plasma metabolite-based ALC and AH noninvasive differential diagnosis model, which is characterized in that five plasma key metabolites are taken as core indexes, and a probability calculation model is constructed through a logistic regression algorithm; the five kinds of plasma key metabolites are respectively an Ab-fubinaca metabolite 3, isocitric acid, N-docosahexaenoyl cysteine, gluconic acid-delta-lactone, and 1-palmitoyl-2-linoleyl phosphatidylethanolamine. The invention further provides a construction method and application of the model. According to the method, five key plasma metabolites with remarkable difference between AH and ALC are screened, modeling is carried out in combination with a logistic regression algorithm, or a multi-parameter model is constructed by further integrating prothrombin time, so that accurate non-invasive efficient identification of AH and ALC is realized.

The invention discloses an abnormal prothrombin antibody and application thereof, and relates to the field of antibodies. The abnormal prothrombin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of abnormal prothrombin, and has good affinity or activity.

The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention relates to a method for rapidly detecting the activity of human thrombin in a human prothrombin complex, and belongs to the technical field of biological product detection. The method comprises the following steps: diluting a human thrombin solution into a plurality of gradients in equal proportion, then adding a fibrinogen solution, standing for a period of time, observing whether clots or fibrin are separated out, and determining the corresponding human thrombin activity titer limit when the clots or fibrin are separated out; mixing the human prothrombin complex with a fibrinogen solution, and detecting the refractive index under the wavelength of 589 nm; and determining the activity of the human thrombin in the human prothrombin complex by comparing the refractive index values. According to the method, the original 24-hour test time is shortened to be within 1 hour, and the problem that the time of an existing method for testing the activity of the human thrombin in the human prothrombin complex is too long is solved.

The invention relates to the technical field of antibodies, in particular to an abnormal prothrombin (PIVKA-II) antibody or a conjugate thereof and application thereof. The antibody or the conjugate thereof comprises a heavy chain variable region VH and a light chain variable region VL, the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH are respectively shown as SEQ ID No: 1-3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region VL are respectively shown as SEQ ID No: 4-5; the antibody conjugate is formed by coupling the antibody with a marker or a solid-phase carrier. The antibody disclosed by the invention has high binding activity and affinity to PIVKA-II, and the specificity, sensitivity, reliability and accuracy detection of trace PIVKA-II in a sample can be realized in a double-antibody sandwich manner.

Provided in the present invention is an anti-prothrombin / phosphatidylserine antibody, comprising a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises HCDR1 to HCDR3 having amino acid sequences as shown in SEQ ID NOs: 1-3, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having amino acid sequences as shown in SEQ ID NOs: 4-6, respectively. The anti-prothrombin / phosphatidylserine antibody of the present invention can bind to a prothrombin / phosphatidylserine complex with high affinity, thereby targeting and binding to phosphatidylserine, and has a potential therapeutic effect with respect to tumors, infections, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, etc.

The invention belongs to the technical field of biology, and particularly relates to an anti-human thrombin-antithrombin complex antibody and a preparation method and application thereof and a preparation method of an anti-human thrombin-antithrombin complex (TAT), and the preparation method is characterized by comprising the following steps: (1) expressing and purifying human prothrombin (PT) and human antithrombin III (AT-III); (2) activating PT by using Ecarin snake venom to obtain thrombin (T); and (3) mixing T and AT-III according to a mass ratio of 0.7: 1 for reaction, and purifying to obtain the TAT complex, the invention also comprises a monoclonal antibody secreted by a hybridoma cell strain TAT-2F for specific recognition of TAT and a monoclonal antibody secreted by a hybridoma cell strain T-5B for specific recognition of T and TAT, and the monoclonal antibody provided by the invention can be combined with TAT with high specificity, so that the TAT complex can be used for detecting TAT and TAT. Therefore, the monoclonal antibody can be used for identifying or detecting a patient with abnormal blood coagulation.

The invention belongs to the technical field of liver disease detection markers, and particularly relates to a biomarker combination for detecting liver cirrhosis, liver cancer, hepatitis combined with liver cancer and liver cirrhosis combined with liver cancer and application, the combined marker comprises chitosanase 3-like protein 1, alpha fetoprotein, alpha fetoprotein variant L3 ratio, abnormal prothrombin or Golgi protein 73, alpha fetoprotein, alpha fetoprotein variant L3 ratio, alpha fetoprotein variant L3 ratio and alpha fetoprotein variant L3 ratio. When the level of each component of the detected person is higher than a preset critical value, the corresponding disease is evaluated to be high in risk, and when the level of each component of the detected person is lower than the preset critical value, the corresponding disease is evaluated to be low in risk. The kit has the characteristics of high accuracy, strong specificity and high sensitivity, is also beneficial to detection of liver cirrhosis, liver cancer or hepatitis combined liver cancer which is not easy to detect, and can help patients to diagnose liver cirrhosis, liver cancer, hepatitis combined liver cancer or liver cirrhosis combined liver cancer as early as possible, so that the healing and survival probability is increased.